CDK12 inactivation across solid tumors: an actionable genetic subtype

Oncoscience
Catherine H MarshallEmmanuel S Antonarakis

Abstract

Inactivating CDK12 alterations have been reported in ovarian and prostate cancers and may have therapeutic implications; however, the prevalence of these mutations across other cancer types is unknown. We searched the cBioPortal and GENIE Project (public release v4.1) databases for cancer types with > 200 sequenced cases, that included patients with metastatic disease, and in which the occurrence of at least monoallelic CDK12 alterations was > 1%. The prevalence of at least monoallelic CDK12 mutations was highest in bladder cancer (3.7%); followed by prostate (3.4%), esophago-gastric (2.1%) and uterine cancers (2.1%). Biallelic CDK12 inactivation was highest in prostate cancer (1.8%), followed by ovarian (1.0%) and bladder cancers (0.5%). These results are the first (to our knowledge) to estimate the prevalence of monoallelic and biallelic CDK12 mutations across multiple cancer types encompassing over 15,000 cases.

References

Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Sep 24, 2016·Cancer Treatment Reviews·Rosaria ChilàGiovanna Damia
Jun 3, 2017·Cancer Discovery·UNKNOWN AACR Project GENIE Consortium
Sep 13, 2018·The New England Journal of Medicine·Emmanuel S Antonarakis

❮ Previous
Next ❯

Citations

Aug 6, 2020·International Journal of Molecular Sciences·Tae Jin Kim, Kyo Chul Koo
Dec 10, 2020·Future Medicinal Chemistry·Solomon TadesseAndrii Monastyrskyi
Sep 30, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Pasquale RescignoJohann S de Bono
Mar 14, 2020·Current Opinion in Oncology·Catherine H Marshall, Emmanuel S Antonarakis
Nov 8, 2020·International Journal of Molecular Sciences·Antje M WengnerBernard Haendler
Jan 25, 2020·Cancer Treatment and Research Communications·Catherine Handy Marshall, Emmanuel S Antonarakis
Feb 26, 2021·Journal of Immunology Research·Bikang YangYincheng Teng

❮ Previous
Next ❯

Methods Mentioned

BETA
genotyping

Clinical Trials Mentioned

NCT03570619

Software Mentioned

cBioPortal
GENIE

Related Concepts

Related Feeds

CZI Human Cell Atlas Seed Network

The aim of the Human Cell Atlas (HCA) is to build reference maps of all human cells in order to enhance our understanding of health and disease. The Seed Networks for the HCA project aims to bring together collaborators with different areas of expertise in order to facilitate the development of the HCA. Find the latest research from members of the HCA Seed Networks here.

Related Papers

International Journal of Cancer. Journal International Du Cancer
Paolo PeterlongoNathan A Ellis
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Gopa IyerDavid B Solit
Kansas Medicine : the Journal of the Kansas Medical Society
D E Gray
Journal of the American College of Radiology : JACR
Bruce J Hillman
© 2021 Meta ULC. All rights reserved